Alternative Dosing Schedules for Irinotecan

ONCOLOGY

Volumn 12, Issue 8 SUPPL., 1998, Pages 68-71

  Rothenberg, Mace L ^a   Kuhn, John G ^b   Schaaf, Larry J ^c   Drengler, Ronald L ^d   Gail Eckhardt, S ^d   Villalona Calero, Miguel A ^d   Hammond, Lisa ^b   Miller, Langdon L ^c   Petit, Robert G ^c   Rowinsky, Eric K ^d   Von Hoff, Daniel D ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c PFIZER INC   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIEMETIC AGENT; CARBOXYLESTERASE; DEXAMETHASONE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST;

ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS;

EID: 0031795669     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Beidler DR, Cheng YC: Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47:907- 914, 1995.
2. Rothenberg ML: CPT-11. An original spectrum of clinical activity. Semin Oncol 23(1;suppl 3):21-26, 1996.
3. Chen AY, Lm LF: Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat Res 73 263-281, 1994.
4. Shimada Y, Rothenberg M, Hilsenbeck SG, et al: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5:202-206, 1994.
5. Saltz L, Early E, Kelsen D, et al: Phase I study of chronic daily low-dose irinotecan (CPT- 11) (abstract). Proc Am Soc Clin Oncol 16:200a, 1997.
6. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994.
7. Houghton PJ, Cheshire PJ, Mailman JD II, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors Cancer Chemother Pharmacol 36:393-403, 1995.
8. Thompson J, Zamboni WC, Cheshire PJ, et al: Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:423-432, 1997.
9. 2 given every-other-week in previously treated colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 17:284a, 1998.